Mammographic Density and Risk of Second Breast Cancer after Ductal Carcinoma In situ

Background: We examined whether mammographic density predicts risk of second breast cancers among patients with ductal carcinoma in situ (DCIS). Methods: The study included DCIS patients diagnosed during 1990 to 1997 and treated with breast-conserving surgery at Kaiser Permanente Northern California. Medical records were reviewed for clinical factors and subsequent breast cancers (DCIS and invasive). Ipsilateral mammograms from the index DCIS were assessed for density without knowledge of subsequent cancer status. Cox regression modeling was used to examine the association between mammographic density and risk of breast cancer events. Results: Of the 935 eligible DCIS patients, 164 (18%) had a subsequent ipsilateral breast cancer, and 59 (6%) had a new primary cancer in the contralateral breast during follow-up (median, 103 mo). Those with the greatest total area of density (upper 20% of values) were at increased risk for invasive disease in either breast [hazard ratio (HR), 2.1; 95% confidence interval (95% CI), 1.2-3.8] or any cancer (DCIS or invasive) in the ipsilateral (HR, 1.7; 95% CI, 1.0-2.9) or contralateral (HR, 3.0; 95% CI, 1.3-6.9) breast compared with those with the smallest area of density (bottom 20%). HRs for these same end points comparing those in the highest with those in the lowest American College of Radiology Breast Imaging Reporting and Data System category were 1.6 (95% CI, 0.7-3.6), 1.3 (95% CI, 0.7-2.6), and 5.0 (95% CI, 1.4-17.9), respectively. There was a suggestion of increasing risk of contralateral, but not ipsilateral, cancer with increasing percent density. Conclusions: Women with mammographically dense breasts may be at higher risk of subsequent breast cancer, especially in the contralateral breast. Impact: Information about mammographic density may help with DCIS treatment decisions. Cancer Epidemiol Biomarkers Prev; 19(10); 2488–95. ©2010 AACR.

[1]  B. Hulka,et al.  Steroid hormones and risk of breast cancer , 1994, Cancer.

[2]  D. Schultz,et al.  Mammographically detected ductal carcinoma in situ of the breast treated with breast-conserving surgery and definitive breast irradiation: long-term outcome and prognostic significance of patient age and margin status. , 2001, International journal of radiation oncology, biology, physics.

[3]  Linda Olson,et al.  Effects of Estrogen and EstrogenProgestin on Mammographic Parenchymal Density , 1999, Annals of Internal Medicine.

[4]  R N Hoover,et al.  Mammographic densities and risk of breast cancer , 1991, Cancer.

[5]  M. Pike,et al.  Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. , 1993, Epidemiologic reviews.

[6]  D. Trichopoulos,et al.  Mammary Gland Mass and Breast Cancer Risk , 1992, Epidemiology.

[7]  T. Tuttle,et al.  Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  K. Kerlikowske,et al.  Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program. , 2000, Archives of internal medicine.

[9]  N. Boyd,et al.  Relationship between mammographic and histological risk factors for breast cancer. , 1992, Journal of the National Cancer Institute.

[10]  R. J. Brenner Conjugated Equine Estrogen Influence on Mammographic Density in Postmenopausal Women in a Substudy of the Women's Health Initiative Randomized Trial , 2010 .

[11]  N. Boyd,et al.  Mammographic densities and breast cancer risk. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[12]  Ikuko Kato,et al.  A nested case-control study of mammographic patterns, breast volume, and breast cancer (New York City, NY, United States) , 1995, Cancer Causes & Control.

[13]  J Costantino,et al.  Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight‐year update of Protocol B‐17 , 1999, Cancer.

[14]  Pathologic findings from the national surgical adjuvant breast project (NSABP) eight‐year update of protocol B‐17 , 2000, Cancer.

[15]  Laurence L. George,et al.  The Statistical Analysis of Failure Time Data , 2003, Technometrics.

[16]  M. Pike,et al.  Changes in mammographic densities induced by a hormonal contraceptive designed to reduce breast cancer risk. , 1994, Journal of the National Cancer Institute.

[17]  V T Farewell,et al.  The analysis of failure times in the presence of competing risks. , 1978, Biometrics.

[18]  J. Stanford,et al.  Risk of recurrence after ductal carcinoma in situ of the breast. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[19]  N. Boyd,et al.  Mammographic density. Potential mechanisms of breast cancer risk associated with mammographic density: hypotheses based on epidemiological evidence , 2008, Breast Cancer Research.

[20]  A. Oza,et al.  Mammographic parenchymal patterns: a marker of breast cancer risk. , 1993, Epidemiologic reviews.

[21]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[22]  K. Chew,et al.  High mammographic breast density is independent predictor of local but not distant recurrence after lumpectomy and radiotherapy for invasive breast cancer. , 2009, International journal of radiation oncology, biology, physics.

[23]  R N Hoover,et al.  Mammographic parenchymal patterns as indicators of breast cancer risk. , 1989, American journal of epidemiology.

[24]  J. Costantino,et al.  Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  D. Miglioretti,et al.  Individual and Combined Effects of Age, Breast Density, and Hormone Replacement Therapy Use on the Accuracy of Screening Mammography , 2003, Annals of Internal Medicine.

[26]  Stephen W Duffy,et al.  Tamoxifen and breast density in women at increased risk of breast cancer. , 2004, Journal of the National Cancer Institute.

[27]  L. Kolonel,et al.  The association of mammographic density with ductal carcinoma in situ of the breast: the Multiethnic Cohort , 2006, Breast Cancer Research.

[28]  C. Byrne,et al.  Studying mammographic density: implications for understanding breast cancer. , 1997, Journal of the National Cancer Institute.

[29]  D. Miglioretti,et al.  Association between Breast Density and Subsequent Breast Cancer Following Treatment for Ductal Carcinoma In situ , 2007, Cancer Epidemiology Biomarkers & Prevention.

[30]  A. Miller,et al.  Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. , 1995, Journal of the National Cancer Institute.

[31]  J. Wolfe,et al.  Mammographic parenchymal patterns and quantitative evaluation of mammographic densities: a case-control study. , 1987, AJR. American journal of roentgenology.

[32]  N. Krieger Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. , 1992, American journal of public health.

[33]  J. Wolfe,et al.  Mammographic features and breast cancer risk: effects with time, age, and menopause status. , 1995, Journal of the National Cancer Institute.

[34]  S. Joslyn Ductal Carcinoma in Situ: Trends in Geographic, Temporal, and Demographic Patterns of Care and Survival , 2006, The breast journal.

[35]  M S Pepe,et al.  Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data? , 1993, Statistics in medicine.

[36]  K. Kerlikowske,et al.  Detection of ductal carcinoma in situ in women undergoing screening mammography. , 2002, Journal of the National Cancer Institute.

[37]  James Dignam,et al.  Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial , 1999, The Lancet.

[38]  N. Gordon,et al.  Some evidence refuting the HMO "favorable selection" hypothesis: the case of Kaiser Permanente. , 1991, Advances in health economics and health services research.

[39]  R. Hiatt,et al.  The frequency of kidney and urinary tract diseases in a defined population. , 1982, Kidney international.

[40]  S. Ingles,et al.  Serum prolactin levels are positively associated with mammographic density in postmenopausal women , 2007, Breast Cancer Research and Treatment.

[41]  Gary J. Whitman,et al.  Mammographic density and the risk of breast cancer recurrence after breast-conserving surgery , 2010 .

[42]  N. Weiss,et al.  Risk of contralateral breast cancer among women with carcinoma in situ of the breast. , 1997, Annals of surgery.

[43]  E White,et al.  Variation in mammographic breast density by time in menstrual cycle among women aged 40-49 years. , 1998, Journal of the National Cancer Institute.

[44]  V. McCormack,et al.  Breast Density and Parenchymal Patterns as Markers of Breast Cancer Risk: A Meta-analysis , 2006, Cancer Epidemiology Biomarkers & Prevention.

[45]  M. Szklo,et al.  Mammographic parenchymal patterns and breast cancer risk. , 1987, Epidemiologic reviews.

[46]  N F Boyd,et al.  The association of breast mitogens with mammographic densities , 2002, British Journal of Cancer.

[47]  James J Dignam,et al.  Mammographic density and breast cancer after ductal carcinoma in situ. , 2004, Journal of the National Cancer Institute.

[48]  T. Tuttle,et al.  Trends in the treatment of ductal carcinoma in situ of the breast. , 2004, Journal of the National Cancer Institute.